Matching articles for "Haldol"
Issue 1510 · December 19, 2016
Drugs for Psychotic Disorders

Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs…

Med Lett Drugs Ther. 2016 Dec 19; 58(1510):160-4
Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs used for treatment of these disorders are listed in Table 2.
Issue 1481 · November 9, 2015
Two Long-Acting Injectable Antipsychotics for Schizophrenia

The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil ( Aristada – Alkermes), which is given once every…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):152-3
The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil ( Aristada – Alkermes), which is given once every 4-6 weeks, and paliperidone palmitate ( Invega Trinza – Janssen), which is given once every 3 months. Once-monthly injectable formulations of aripiprazole (Abilify Maintena) and paliperidone palmitate (Invega Sustenna) were approved earlier.
Issue 1440 · April 14, 2014
Inhaled Loxapine (Adasuve) for Acute Agitation

The FDA has approved an inhalation powder formulation of loxapine ( Adasuve – Teva), a first-generation antipsychotic long available in an oral formulation, for treatment of acute agitation related to…

Med Lett Drugs Ther. 2014 Apr 14; 56(1440):31-2
The FDA has approved an inhalation powder formulation of loxapine ( Adasuve – Teva), a first-generation antipsychotic long available in an oral formulation, for treatment of acute agitation related to schizophrenia or bipolar I disorder in adults. Adasuve is the first inhaled drug to be approved for this indication.
Issue 130 · June 1, 2013
Drugs for Psychiatric Disorders

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them…

Treat Guidel Med Lett. 2013 Jun; 11(130):53-64
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Issue 1415 · April 29, 2013
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia

An extended-release injectable formulation of the second-generation antipsychotic aripiprazole (Abilify) has been approved by the FDA ( Abilify Maintena – Otsuka/Lundbeck) for once-monthly treatment of…

Med Lett Drugs Ther. 2013 Apr 29; 55(1415):34-6
An extended-release injectable formulation of the second-generation antipsychotic aripiprazole (Abilify) has been approved by the FDA ( Abilify Maintena – Otsuka/Lundbeck) for once-monthly treatment of schizophrenia. It is the fourth second-generation antipsychotic to become available in a long-acting parenteral formulation. Long-acting parenteral antipsychotics, given at intervals of 2-4 weeks, are generally used for patients with a history of relapse due to poor adherence to oral maintenance therapy.
Issue 1374 · October 3, 2011
Quetiapine (Seroquel) and QT-Interval Prolongation

The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs…

Med Lett Drugs Ther. 2011 Oct 3; 53(1374):79-80
The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs that prolong the electrocardiographic QTc interval (Table 1). The warning is based only on postmarketing reports of QT-interval prolongation in patients who overdosed on the drug, had concomitant illness, or were taking other drugs known to cause electrolyte imbalances or increase the QT interval. QT prolongation can lead to torsades de pointes, a potentially fatal cardiac arrhythmia.
Issue 1331 · February 8, 2010
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder

Asenapine ( Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated…

Med Lett Drugs Ther. 2010 Feb 8; 52(1331):9-10
Asenapine ( Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder.
Issue 1322 · October 5, 2009
Dronedarone (Multaq) for Atrial Fibrillation

Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but…

Med Lett Drugs Ther. 2009 Oct 5; 51(1322):78-80
Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Issue 1306 · February 23, 2009 Free
In Brief: Cardiac Risks of Antipsychotic Drugs

A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death.…

Med Lett Drugs Ther. 2009 Feb 23; 51(1306):13
A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death. Typical antipsychotics have long been associated with this risk. In this study, however, the incidence of sudden cardiac death was similar with typical and atypical antipsychotics: about 1 in 340 person-years among the patients who took typical (first generation) antipsychotics such as haloperidol ( Haldol , and others) and 1 in 360 personyears among those who took atypical (second-generation) drugs such as olanzapine (Zyprexa) , compared to 1 in 700 patient-years among otherwise similar nonusers of antipsychotic drugs. The risk increased with the dose of the drug and also with the age of the patient; the authors state that they did not include patients younger than 30 because sudden cardiac death is very rare in the younger age group. 1 Second-generation drugs are less likely than first generation drugs to cause extrapyramidal symptoms, tardive dyskinesia and neuroleptic malignant syndrome, but more likely to cause weight gain and other metabolic abnormalities. 2 Aripiprazole (Abilify) 3 is least likely to prolong the QT interval, which is one of the mechanisms that could be responsible for the small increase in the absolute risk of sudden death among patients who take antipsychotic drugs. In a patient with a good indication for its use, the consequences of not taking an antipsychotic drug may be greater than the risks of taking one. 1. WA Ray et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225. 2. Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35. 3. Second-generation antipsychotics — aripiprazole revisited. Med Lett Drugs Ther 2005; 47:81. Download: U.S. English
Issue 1304 · January 26, 2009
Tetrabenazine (Xenazine) for Huntington's Chorea

Tetrabenazine ( Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with…

Med Lett Drugs Ther. 2009 Jan 26; 51(1304):7-8
Tetrabenazine ( Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.
Issue 1215 · August 15, 2005
AmpliChip CYP450 Test

The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):71-2
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.
Issue 1214 · August 1, 2005
Atypical Antipsychotics in the Elderly

The FDA has reported that 5106 elderly patients with dementia treated with atypical (second generation) antipsychotics in 17 randomized controlled trials had a higher mortality rate (4.5% vs. 2.6%) than those…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):61-2
The FDA has reported that 5106 elderly patients with dementia treated with atypical (second generation) antipsychotics in 17 randomized controlled trials had a higher mortality rate (4.5% vs. 2.6%) than those receiving placebo. Most of the deaths were due to cardiovascular and infectious causes (such as pneumonia). The drugs used in the trials were aripiprazole (Abilify) , olanzapine (Zyprexa) , quetiapine (Seroquel) , and risperidone (Risperdal) . As the increase in mortality was considered a class effect, the FDA advisory also included ziprasidone (Geodon) , clozapine (Clozaril) and the olanzapine/fluoxetine combination (Symbyax) . The manufacturers of all of these drugs will be required to add a "black box" warning to their labeling.
Issue 1172 · December 22, 2003
Choice of an Antipsychotic

A recent supplement to the Journal of Clinical Psychiatry , titled "The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders," concluded that most experts endorsed use…

Med Lett Drugs Ther. 2003 Dec 22; 45(1172):102-4
A recent supplement to the Journal of Clinical Psychiatry , titled "The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders," concluded that most experts endorsed use of second-generation (atypical) antipsychotics rather than first-generation drugs, with risperidone ( Risperdal - Janssen) the top choice for first episodes, multiple episodes or switches from another drug (JM Kane et al, J Clin Psychiatry 2003; 64 suppl 12:5). The supplement was sponsored by Janssen.
Issue 11 · July 1, 2003
Drugs for Psychiatric Disorders

The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and…

Treat Guidel Med Lett. 2003 Jul; 1(11):69-76
The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 2003 .
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1150 · February 17, 2003
Aripiprazole (Abilify) for Schizophrenia

Aripiprazole ( Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.

Med Lett Drugs Ther. 2003 Feb 17; 45(1150):15-6
Aripiprazole ( Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Issue 1016 · December 19, 1997
Quetiapine for Schizophrenia

Quetiapine ( Seroquel - Zeneca), a dibenzothiazepine derivative, has been approved by the FDA for treatment of schizophrenia and other psychotic disorders. It is a new addition to the 'atypical'…

Med Lett Drugs Ther. 1997 Dec 19; 39(1016):117-8
Quetiapine ( Seroquel - Zeneca), a dibenzothiazepine derivative, has been approved by the FDA for treatment of schizophrenia and other psychotic disorders. It is a new addition to the 'atypical' antipsychotics, which include olanzapine ( Zyprexa - Medical Letter, 39:5, 1997), risperidone ( Risperdal ) and clozapine ( Clozaril ). Atypical antipsychotic drugs generally are less likely to cause extrapyramidal symptoms than older drugs such as haloperidol ( Haldol , and others) or the phenothiazines.
Issue 998 · April 11, 1997
Drugs for Psychiatric Disorders

The number of new drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and…

Med Lett Drugs Ther. 1997 Apr 11; 39(998):33-40
The number of new drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions , 1997.
Issue 992 · January 19, 1997
Olanzapine for Schizophrenia

Olanzapine ( Zyprexa - Lilly), a thienobenzodiazepine that structurally resembles and binds to many of the same receptors as clozapine ( Clozaril ), is now available in the USA for treatment of schizophrenia…

Med Lett Drugs Ther. 1997 Jan 19; 39(992):5-6
Olanzapine ( Zyprexa - Lilly), a thienobenzodiazepine that structurally resembles and binds to many of the same receptors as clozapine ( Clozaril ), is now available in the USA for treatment of schizophrenia and other psychotic disorders.
Issue 920 · April 15, 1994
Risperidone for Chronic Schizophrenia

Risperidone ( Risperdal - Janssen), a benzisoxazole derivative, is now available in the USA for treatment of schizophrenia and other psychotic disorders.

Med Lett Drugs Ther. 1994 Apr 15; 36(920):33-4
Risperidone ( Risperdal - Janssen), a benzisoxazole derivative, is now available in the USA for treatment of schizophrenia and other psychotic disorders.
Issue 895 · April 30, 1993
Zolpidem For Insomnia

Zolpidem ( Ambien - Searle), an imidazopyridine hypnotic available in Europe for several years, was recently approved by the US Food and Drug Administration for short-term treatment of insomnia.

Med Lett Drugs Ther. 1993 Apr 30; 35(895):35-6
Zolpidem ( Ambien - Searle), an imidazopyridine hypnotic available in Europe for several years, was recently approved by the US Food and Drug Administration for short-term treatment of insomnia.
Issue 828 · October 5, 1990
Acute Reactions to Drugs of Abuse
Med Lett Drugs Ther. 1990 Oct 5; 32(828):92-4
Issue 826 · September 7, 1990
Fluoxetine (Prozac) Revisited

In the short time since fluoxetine ( Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports,…

Med Lett Drugs Ther. 1990 Sep 7; 32(826):83-4
In the short time since fluoxetine ( Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports, however, have questioned its safety.
Issue 809 · January 12, 1990
Clozapine for Schizophrenia

Clozapine ( Clozaril - Sandoz), a dibenzodiazepine antipsychotic drug that has been available in Europe for many years, was recently approved for marketing by the US Food and Drug Administration. Because of…

Med Lett Drugs Ther. 1990 Jan 12; 32(809):3-4
Clozapine ( Clozaril - Sandoz), a dibenzodiazepine antipsychotic drug that has been available in Europe for many years, was recently approved for marketing by the US Food and Drug Administration. Because of its toxicity, the labeling for clozapine recommends using the drug only for schizophrenic patients who have not responded adequately to standard antipsychotic drugs or have had intolerable adverse effects.
Issue 756 · January 1, 1988
Nabilone And Other Antiemetic For Cancer Patients

Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and…

Med Lett Drugs Ther. 1988 Jan 1; 30(756):2-4
Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol ( Marinol ), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide ( Reglan - Medical Letter, 24:67, 1982), prochlorperazine ( Compazine ; and others), haloperidol ( Haldol ; and others), and corticosteroids. Benzodiazepines, such as lorazepam ( Ativan ; and others), are used to treat anticipatory nausea and vomiting that occurs before chemotherapy begins.